Discussions

Cancer is recognized as one of the deadliest diseases, accounting for an alarming global toll of approximately 20 million new cases and 10 million fatalities.

During research, several partnerships and collaborations that have been inked between different stakeholders engaged in the field of oncology precision medicine market which were identified

According to Roots Analysis, the oncology precision medicine market, valued at USD 166 billion in 2025, is project to reach USD 185 billion in 2026 and USD 364 billion by 2035, representing a CAGR of 7.8% during the forecast period 2026 to 2035.

It is worth mentioning that the number of partnerships inked in this domain has increased over time at a CAGR of 16%, during the period 2018-2023. Most of the deals (32%) were drug licensing agreements, wherein companies licensed their respective drugs to other players to develop and commercialize the drug. Notable examples of drug licensing agreements include (in reverse chronological order, signed in 2023) collaboration between Exscientia and Merck (September 2023), ImmunoGen and Takeda Pharmaceutical (August 2023), Hansoh Pharmaceuticals and Antengene (August 2023), KSQ Therapeutics and Roche (July 2023), Bayer and Cedilla Therapeutics (June 2023), Scorpion Therapeutics and Pierre Fabre (April 2023) and Corbus Pharmaceuticals and CSPC Pharmaceutical (February 2023).

In addition, maximum number of collaborations have been inked by players based in North America; of which 49% deals are intracontinental agreements and 26% deals are intercontinental agreements. Further, the majority of the players based in North America signed intercontinental agreements with stakeholders headquartered in Europe (13%), followed by stakeholders headquartered in Asia-Pacific and rest of the world-based (5%). Examples of deals signed between players based in North America and Europe include (in reverse chronological order, no selection criteria) collaboration between Deciphera Pharmaceuticals and Clinigen (February 2022), Lantern Pharma and The Danish Cancer Society Research Center (January 2022), Rain Oncology and Roche (January 2022), Oncxerna Therapeutics and Mereo BioPharma (January 2020).

Clinical trial analysis – evaluating the overall potential of oncology precision medicine
Most of the clinical trials assessing the safety and effectiveness of these oncology precision medicines in human beings, are in phase II (66%). This can be attributed to the fact that the application of personalized medicine in oncology has shown a remarkable disease control rate of over 40% among patients diagnosed with various fatal cancers. Owing to which, an upsurge has been witnessed in the R&D activity in this domain, and a large number of novel therapeutic molecules have been identified that are being currently evaluated in the early phases of clinical trials. Additionally, it is worth highlighting that 14% of the clinical trials evaluating precision medicines are phase III studies, indicating that in the coming years more targeted drugs are likely to enter the precision oncology market. Further, 2% of the clinical trials are in phase IV, validating the real-world effectiveness (as demonstrated in the observational early phases of clinical trials) of these drugs.

Majority (56.5%) of the clinical trials focused on precision medicine for oncological disorders are actively recruiting. This increase can be attributed to the high response rate (>40%) demonstrated by these drugs in the oncology clinical trials. This has eventually encouraged patients to participate in these clinical trials to obtain favorable treatment outcomes from precision therapies. This is followed by trials that are active, however not recruiting (24%), trials that have been completed (10%) and trials that are not yet recruiting (9%).

Research Methodology
Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the oncology precision medicine market.

Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.

Click to know more about this report -
https://www.rootsanalysis.com/reports/oncology-precision-medicine-market.html